Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats

British Journal of Pharmacology

Volumn 169, Issue 5, 2013, Pages 953-962

  Alencar, Allan K N ^a   Pereira, Sharlene L ^a   Montagnoli, Tadeu L ^a   Maia, Rodolfo C ^a   Kümmerle, Arthur E ^b   Landgraf, Sharon S ^a   Caruso Neves, Celso ^a   Ferraz, Emanuelle B ^a   Tesch, Roberta ^a   Nascimento, José H M ^a   De Sant'Anna, Carlos M R ^b   Fraga, Carlos A M ^a   Barreiro, Eliezer J ^a   Sudo, Roberto T ^a   Zapata Sudo, Gisele ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

A2A adenosine agonist; monocrotaline; pulmonary hypertension; pulmonary vascular remodelling; ventricular dysfunction

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,4 DIMETHOXYPHENYL N METHYLBENZOYLHYDRAZIDE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; LASSBIO 1359; UNCLASSIFIED DRUG; 3,4-DIMETHOXYPHENYL-N-METHYLBENZOYLHYDRAZIDE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; BENZAMIDE DERIVATIVE; COLLAGEN; HYDRAZONE DERIVATIVE; MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG ARTERY; MALE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RECEPTOR UPREGULATION; VASODILATATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IN VITRO STUDY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY ARTERY; VASCULAR ENDOTHELIUM; WISTAR RAT;

ADENOSINE A2 RECEPTOR AGONISTS; ADMINISTRATION, ORAL; ANIMALS; BENZAMIDES; COLLAGEN; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HYDRAZONES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IN VITRO TECHNIQUES; MALE; MOLECULAR DOCKING SIMULATION; MONOCROTALINE; PULMONARY ARTERY; RATS, WISTAR; RECEPTORS, ADENOSINE A2;

EID: 84879028705     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12193     Document Type: Article

References (19)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324
2. Barreiro EJ, (2002). Estratégia de simplificação molecular no planejamento racional de fármacos: a descoberta de novo agente cardioativo. Quim Nova 25: 1172-1180.
3. 2A receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2. Neurotox Res 2: 150-157.
4. 2A) receptor, decreases acute lung inflammation. Eur J Pharmacol 668: 305-316.
5. Jeffery TK, Wanstall JC, (2001). Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92: 1-20.
6. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
7. Koskenvuo JW, Mirsky R, Zhang Y, Angeli FS, Jahn S, Alastalo TP, et al. (2010). A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model. Int J Cardiovasc Imaging 26: 509-518.
8. Kummerle AE, Schmitt M, Cardoso SVS, Lugnier C, Villa P, Lopes AB, et al. (2012). Design, synthesis, and pharmacological evaluation of N-Acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors. J Med Chem 55: 7525-7545.
9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. (2006). Recommendations for chamber quantification. Eur J Echocardiogr 7: 79-108.
10. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
11. McLaughlin VV, McGoon MD, (2006). Pulmonary arterial hypertension. Circulation 114: 1417-1431.
12. +-ATPase and potassium channels. Pharmacol Rep 57: 824-832.
13. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. (2005). Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821.
14. Schermuly RT, Ghofrani MRW, Grimminger F, (2011). Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 8: 443-455.
15. Silva AG, Zapata-Sudo G, Kummerle AE, Fraga CAM, Barreiro EJ, Sudo RT, (2005). Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorg Med Chem 13: 3431-3437.
16. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, et al. (2010). Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927.
17. 2A receptor confers pulmonary arterial hypertension and increased pulmonary vascular remodeling in mice. J Vasc Res 48: 171-183.
18. Zapata-Sudo G, Pereira SL, Beiral HJ, Kummerle AE, Raimundo JM, Antunes F, et al. (2010). Pharmacological characterization of (3-thienylidene)-3,4- methylenedioxybenzoylhydrazide: a novel muscarinic agonist with antihypertensive profile. Am J Hypertens 23: 135-141.
19. Zhang T, Cui B, Dai D, Su W, (2005). CPU 86017, p- chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway. Acta Pharmacol Sin 26: 1309-1316. Tecnológico Nível Superior Pesquisa do Estado do Rio de Janeiro